

MAR 08 2004

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE

OFFICIAL

Applicants Docket Number:  
USST97019US CNT1

Applicants:  
Georges Bashiardes, et al

Serial No.  
09/990,015

Filing Date:  
November 21, 2001

Title of Invention:  
POLYHYDROXYALKYLPYRAZINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS  
COMPRISING THEM

RECEIVED  
MAY 20 2004

OFFICE OF PETITIONS

CERTIFICATE OF TRANSMISSION  
I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at 703-872-9306, on  
Date of Deposit March 8, 2004  
Printed Name of Person Signing Certificate Bonnie Stein  
Signature *Bonnie Stein*

Total Number of Pages Sent: 8

Attorney: Irving Newman

Group Art Unit: 1624

Examiner: Not Assigned

TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |   |  |
|---|--|
| <input type="checkbox"/> Amendment, 37 CFR _____  | <input type="checkbox"/> Fee Transmittal   |
| <input checked="" type="checkbox"/> Charge deposit account, \$1,330.00 under<br>37 C.F.R. 1.17(m) | <input checked="" type="checkbox"/> <u>Petition for Revival of an Application for<br/>Patent Abandoned Unintentionally under<br/>37 C.F.R. 1.137(b) - 2 pgs.</u> |
| <input type="checkbox"/> Extension of Time Petition   | <input checked="" type="checkbox"/> Other <u>Copy of Notice of Abandonment<br/>under 37 C.F.R. 1.53(f) or (g) dated<br/>11/5/03 - 1 pg.</u>                      |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order                                    | <input checked="" type="checkbox"/> Other <u>Completion of Filing<br/>Requirements - Nonprovisional<br/>Application- 1 pg.; Abstract - 2 pgs.</u>                |
| <input type="checkbox"/> Maintenance Fee Transmittal  | <input checked="" type="checkbox"/> Other: <u>Copy of Notice to File Corrected<br/>Application Papers, date mailed 11/30/02<br/>- 1 pg.</u>                      |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

MAR. 8. 2004 2:59PM

AVENTIS US PAT DEPT

NO. 0154

OFFICIAL

RECEIVED

MAY 20 2004

Aventis File No.: USST97019 US CNT 1

OFFICE OF PETITIONS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

MAR 08 2004

First Named Inventor: Georges Bashiardes, et al  
Serial No.: 09/990,015  
Filing Date: November 21, 2001  
For: POLYHYDROXYALKYLPYRAZINE DERIVATIVES,  
THEIR PREPARATION AND MEDICAMENTS  
COMPRISING THEM  
Group Art Unit: 1624  
Examiner: Not assigned

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, at 703-872-9306, on  
Date of Deposit March 8, 2004  
Printed Name of Person Signing Certificate Bonnie Stein  
Signature Bonnie Stein

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED  
UNINTENTIONALLY  
UNDER 37 C.F.R. § 1.137(b)

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Dear Sirs:

04/22/2004 PSTANBAC 00000001 181982 The above-referenced application became abandoned for failure to file a timely  
and proper reply to the Notice to File Corrected Application Papers issued by the  
USPTO on November 30, 2001. The Notice of Abandonment Under 37 CFR 1.53 dated  
November 5, 2003, copy enclosed, was received on November 7, 2003. This Petition is  
being filed under 37 C.F.R. § 1.137(b) to request that the Commissioner revive said  
application.

Aventis File No.: USST97019 US CNT 1

being filed under 37 C.F.R. § 1.137(b) to request that the Commissioner revive said application.


As required, this petition includes the following items:

- (1) Petition fee of \$1330.00 (37 CFR 1.17(m));
- (2) Response To The Notice To File Corrected Application Papers (attached);
- (3) A statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional.
- (4) A terminal disclaimer is not required since this application was filed before June 8, 1995.

Applicants' attorney confirms that the entire delay in filing the required reply from the due date of the response to the filing of this petition has been unintentional. After review of the file, it was discovered that The Notice to File Corrected Application Papers was timely received, however, was inadvertently missed and not properly docketed nor identified as requiring a response. Once the error was identified, the applicants' attorney timely prepared and filed this petition.

The Commissioner is hereby authorized to charge the above fees and any other fees required by the filing of this Petition, or credit any overpayment, to Deposit Account 18-1982.

Respectfully submitted,  
Georges Bashiardes, ET AL.



Irving Newman  
Registration No. 22,638

Customer No. 005487  
Aventis Pharmaceuticals Inc.  
Mail Stop D-303A  
Route 202-206  
Bridgewater, NJ 08807-0800  
Telephone: (908) 231-2785  
Fax No. (908) 231-2626

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Georges Bashiardes, et al.**

Examiner: Not assigned

Art Unit: 1624

Application No.: 09/990,015

Filed: November 21, 2001

Title: POLYHYDROXYALKYLPYRAZINE  
DERIVATIVES, THEIR  
PREPARATION AND  
MEDICAMENTS COMPRISING  
THEM

**COMPLETION OF FILING REQUIREMENTS -  
NONPROVISIONAL APPLICATION**


Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

This replies to the Notice of Corrected Application Papers mailed November 30, 2001. A copy of the Notice of Corrected Application Papers is enclosed.

Submitted herewith is the required abstract which was not provided with the initial filing of the application.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Account No. 18-1982.

Respectfully submitted,

  
Irving Newman  
Registration No. 22,638  
Attorney/Agent for Applicant

Customer No. 005487  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-2785  
Telefax: 908-231-2626

Aventis Docket No.: USST97019 US CNT 1

MAR. 8. 2004 3:00PM

AVENTIS US PAT DEPT

NO. 0154 P. 8

Page 1 of 1



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
WWW.USPTO.GOV

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/990,015	11/21/2001	Georges Bashiardes	ST97619USONAT

005487  
AVENTIS PHARMACEUTICALS, INC.  
PATENTS DEPARTMENT  
ROUTE 202-206, P.O. BOX 6800  
BRIDGEWATER, NJ 08807-0800

CONFIRMATION NO. 2585

FORMALITIES LETTER



\*OC000000007143885\*

Date Mailed: 11/30/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

*A copy of this notice **MUST** be returned with the reply.*

H.T

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE